Immh-010 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating immh-010, 1 is phase 1/phase 2 (1 open).

PD-L1 High Expression (TPS >= 50%), PD-L1 Low Expression (TPS = 1-49.999%), and PD-L1 No Expression are the most frequent biomarker inclusion criteria for immh-010 clinical trials.

Malignant solid tumor and non-small cell lung carcinoma are the most common diseases being investigated in immh-010 clinical trials [2].